Immuneering (IMRX) Capital Expenditures (2020 - 2026)
Immuneering's (IMRX) quarterly Capital Expenditures came in at $79930.0 in Q1 2026, up 793.57% year-on-year from $8945.0 in Q1 2025, and down 35.49% quarter-over-quarter from $123910.0 in Q4 2025.
Immuneering (IMRX) Capital Expenditures (2020 - 2026) Analysis & Trends
Immuneering's Capital Expenditures history runs 7 years deep, the most recent figure standing at $79930.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures rose 793.57% year-over-year to $79930.0 in Q1 2026; TTM through Mar 2026 was $213211.0, a 278.42% increase from a year earlier, with the FY2025 full-year figure at $142226.0, up 67.57% from the prior year.
- Capital Expenditures retreated to $79930.0 in Q1 2026 per IMRX's latest filing, from $123910.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $393134.0 in Q3 2022 and bottomed at $2116.0 in Q2 2025.
- The 5-year median for Capital Expenditures is $57149.0 (2023), against an average of $81897.6.
- Across the five-year window, Capital Expenditures soared 3364.96% in 2022 and slumped 94.53% in 2024, its largest moves.
- Year by year, Capital Expenditures stood at $69302.0 in 2022, then jumped by 146.63% to $170918.0 in 2023, then slumped by 94.53% to $9356.0 in 2024, then surged by 1224.39% to $123910.0 in 2025, then slumped by 35.49% to $79930.0 in 2026.
- Per Business Quant, the three latest IMRX Capital Expenditures figures stand at $79930.0 (Q1 2026), $123910.0 (Q4 2025), and $7255.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 786,000.00 |
| 10 | Immuneering | 279.33 Mn | 279.33 Mn | - | 79,930.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79,930.00 |
| Mar 31, 2026 | 79,930.00 |
| Dec 31, 2025 | 123,910.00 |
| Dec 31, 2025 | 123,910.00 |
| Sep 30, 2025 | 7,255.00 |
| Sep 30, 2025 | 7,255.00 |
| Jun 30, 2025 | 2,116.00 |
| Jun 30, 2025 | 2,116.00 |
| Mar 31, 2025 | 8,945.00 |
| Mar 31, 2025 | 8,945.00 |
| Dec 31, 2024 | 9,356.00 |
| Dec 31, 2024 | 9,356.00 |
| Sep 30, 2024 | 5,268.00 |
| Sep 30, 2024 | 5,268.00 |
| Jun 30, 2024 | 32,773.00 |
| Jun 30, 2024 | 32,773.00 |
| Mar 31, 2024 | 37,478.00 |
| Mar 31, 2024 | 37,478.00 |
| Dec 31, 2023 | 170,918.00 |
| Dec 31, 2023 | 170,918.00 |